menu
    • menu

    Company profile for Lixte Biotechnology

    NEW Drugs in Dev: 1
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of serine/threonine protein phosphatases that are critical to cel...
    Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of serine/threonine protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Lixte BiotechnologyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    248 Route 25A No. 2 East Setauket, NY 11733
    Telephone
    Telephone
    (631) 830-7092
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://lixte.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    De La Soul's Good Health Summit Feb. 19 at Morehouse College
    De La Soul's Good Health Summit Feb. 19 at Morehouse College

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3222724/0/en/DE-LA-SOUL-LED-GOOD-HEALTH-SUMMIT-LAUNCHES-FEBRUARY-19-AT-MOREHOUSE-COLLEGE.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share
    LIXTE Biotech to Attend DealFlow Conference Jan. 28-29
    LIXTE Biotech to Attend DealFlow Conference Jan. 28-29

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3221630/0/en/LIXTE-Biotechnology-Attending-the-DealFlow-Discovery-Conference-January-28-29.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    LIXTE And Collaborators Expand Clear Cell Ovarian Cancer Trial
    LIXTE And Collaborators Expand Clear Cell Ovarian Cancer Trial

    23 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/23/3209841/0/en/LIXTE-and-its-Collaborators-Expand-Clear-Cell-Ovarian-Cancer-Trial.html

    GLOBENEWSWIRE
    23 Dec 2025
    Share Share
    Lixte Bio Announces $4.3M Direct Offering Under Nasdaq Rules
    Lixte Bio Announces $4.3M Direct Offering Under Nasdaq Rules

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207816/0/en/Lixte-Biotechnology-Holdings-Inc-Announces-4-3-Million-Registered-Direct-Offering-Priced-at-the-Market-Under-Nasdaq-Rules.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Focuses On Oncology Platform With Complementary Modalities
    Focuses On Oncology Platform With Complementary Modalities

    08 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-08/lixtes-strategy-comes-into-focus-building-an-oncology-platform-around-complementary-modalities

    PHARMIWEB
    08 Dec 2025
    Share Share
    LIXTE Levels Up From PP2A Innovation To Multi-Modal Oncology
    LIXTE Levels Up From PP2A Innovation To Multi-Modal Oncology

    03 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-03/lixte-levels-up-from-pp2a-innovation-to-multi-modal-oncology

    PHARMIWEB
    03 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search